BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11198115)

  • 1. [Differential diagnosis of oxyphilic (Hürthle cell) adenomas and carcinomas of the thyroid].
    Tret'iakova MS; Bussolati J
    Arkh Patol; 2000; 62(6):14-8. PubMed ID: 11198115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathologic features, proliferative activity, and cyclin D1 expression in Hurthle cell neoplasms of the thyroid.
    Erickson LA; Jin L; Goellner JR; Lohse C; Pankratz VS; Zukerberg LR; Thompson GB; van Heerden JA; Grant CS; Lloyd RV
    Mod Pathol; 2000 Feb; 13(2):186-92. PubMed ID: 10697277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immunohistochemical study of thyroid Hurthle cells and their neoplasms: the roles of S-100 and HMB-45 proteins.
    Abu-Alfa AK; Straus FH; Montag AG
    Mod Pathol; 1994 Jun; 7(5):529-32. PubMed ID: 7937716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Core I gene is overexpressed in Hürthle and non-Hürthle cell microfollicular adenomas and follicular carcinomas of the thyroid.
    Máximo V; Preto A; Crespo A; Rocha AS; Machado JC; Soares P; Sobrinho-Simões M
    BMC Cancer; 2004 Mar; 4():12. PubMed ID: 15043758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E2F-1 transcription factor is overexpressed in oxyphilic thyroid tumors.
    Volante M; Croce S; Pecchioni C; Papotti M
    Mod Pathol; 2002 Oct; 15(10):1038-43. PubMed ID: 12379749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis.
    Elliott DD; Pitman MB; Bloom L; Faquin WC
    Cancer; 2006 Apr; 108(2):102-9. PubMed ID: 16453320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays.
    Hoos A; Stojadinovic A; Singh B; Dudas ME; Leung DH; Shaha AR; Shah JP; Brennan MF; Cordon-Cardo C; Ghossein R
    Am J Pathol; 2002 Jan; 160(1):175-83. PubMed ID: 11786411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical experience in Hurthle cell tumors].
    Francomano F; Napolitano L; Scipione P; Savini F; Bajocchi G; Angelucci D
    G Chir; 1998; 19(11-12):449-52. PubMed ID: 9882947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hurthle cell neoplasm: our experience].
    Cristofaro MG; Vescio G; Fava MG; Aversa C; Amantea M; Giudice M
    Ann Ital Chir; 2004; 75(6):663-8. PubMed ID: 15960361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunocytochemical expression of Ki67 and laminin in Hurthle cell adenomas and carcinomas.
    Pisani T; Pantellini F; Centanni M; Vecchione A; Giovagnoli MR
    Anticancer Res; 2003; 23(4):3323-6. PubMed ID: 12926070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Thyroidal oxyphilic tumors].
    Sabo R; Zohar Y; Schwartz A; Segal K
    Harefuah; 1994 Feb; 126(4):183-6, 240. PubMed ID: 8168757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hürthle-cell thyroid neoplasms: a clinical enigma].
    Cannizzaro M; Fiorenza G; Garofalo L; De Maria A; Cavallaro N; Pulvirenti A; Veroux PF
    Ann Ital Chir; 1999; 70(4):503-8; discussion 508-9. PubMed ID: 10573612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
    Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
    Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of proliferative activity of thyroid Hürthle cell tumors using PCNA, Ki-67 and AgNOR methods.
    Augustynowicz A; Dziecioł J; Barwijuk-Machała M; Dadan J; Puchalski Z; Sulkowski S
    Folia Histochem Cytobiol; 2004; 42(3):165-8. PubMed ID: 15493577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Follicular and Hurthle cell tumors of the thyroid gland. Possibilities of preoperative differential diagnosis].
    Grineva EN; Goriushkina EV; Malakhova TV; Tsoĭ UA
    Vopr Onkol; 2004; 50(1):41-5. PubMed ID: 15088519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hürthle cell carcinoma is a better gold standard than Hürthle cell neoplasm for fine-needle aspiration of the thyroid: defining more consistent and specific cytologic criteria.
    Renshaw AA
    Cancer; 2002 Oct; 96(5):261-6. PubMed ID: 12378592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases.
    Ghossein RA; Hiltzik DH; Carlson DL; Patel S; Shaha A; Shah JP; Tuttle RM; Singh B
    Cancer; 2006 Apr; 106(8):1669-76. PubMed ID: 16534796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaplastic, sarcomatoid carcinoma of the thyroid originating from a Hürthle cell tumor.
    Okoń K; Wierzchowski W; Jabłońska E; Wójcik P; Steczko A
    Pol J Pathol; 2003; 54(4):277-81. PubMed ID: 14998298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oxyphilic cell and clear cell carcinoma of the thyroid].
    Houcke ML; Patey M
    Arch Anat Cytol Pathol; 1998; 46(1-2):79-85. PubMed ID: 9754362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator activated receptor gamma immunohistochemical expression in human papillary thyroid carcinoma tissues. Possible relationship to lymph node metastasis.
    Galusca B; Dumollard JM; Chambonniere ML; Germain N; Prades JM; Péoc'h M; Estour B
    Anticancer Res; 2004; 24(3b):1993-7. PubMed ID: 15274390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.